X4 PHARMACEUTICALS, INC Derivative Liability, Noncurrent
X4 PHARMACEUTICALS, INC (XFOR) had Derivative Liability, Noncurrent of $369.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Noncurrent $369.00K.
- 2026-03-31: Derivative Liability, Noncurrent $897.00K.
- 2025-12-31: Derivative Liability, Noncurrent $977.00K.
- 2025-09-30: Derivative Liability, Noncurrent $959.00K.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-06-30 | $369.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $897.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $977.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $959.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $283.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $2.92M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $13.76M 10-K · filed 2026-03-17 |
| 2024-09-30 | $11.09M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $9.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $29.44M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $15.68M 10-K · filed 2025-03-26 |
| 2023-09-30 | $22.01M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $47.18M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $17.69M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $23.13M 10-K · filed 2024-03-21 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |